Related Experiment Videos
[Risks of prolonged tocolysis]
1Service de Gynécologie-Obstétrique, Hôtel Dieu, Lyon.
Revue Francaise De Gynecologie Et D'Obstetrique
|October 1, 1994
Summary
Premature delivery treatment involves progestins, prostaglandin inhibitors, and beta-mimetics. Careful prescription and medical follow-up are crucial to minimize risks associated with these potent medications.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
Background:
- Premature delivery affects 4-5% of pregnancies, causing significant fetal morbidity.
- Effective treatments are available but carry inherent risks.
Purpose of the Study:
- To review pharmacological treatments for threatened premature delivery.
- To detail the efficacy, side effects, and necessary medical follow-up for each drug class.
Main Methods:
- Literature review of pharmacological agents used in premature delivery treatment.
- Analysis of drug effects, tolerance, side effects, and contraindications.
Main Results:
- Identified progestins, prostaglandin inhibitors, and beta-mimetics as key treatments.
- Detailed the specific risks, including cardiovascular events with beta-mimetics, and outlined prescription guidelines.
Conclusions:
- Judicious prescription of tocolytic agents, considering contraindications and requiring close medical supervision, is essential.
- Adherence to established treatment protocols can mitigate risks associated with premature delivery management.